{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:29:34Z","timestamp":1790990974822,"version":"4.1.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is an adverse event induced by antiresorptive agents (ARAs). The purpose of this study was to evaluate variables, mainly surgery and hyperbaric oxygen (HBO) therapy, associated with treatment outcomes in patients with a diagnosis of ARONJ at a single center. We enrolled consecutive patients who presented to our hospital for the management of stage 2 or 3 ARONJ between January 2003 and December 2019. The relationship between potentially predictive factors and outcome variables was examined using statistical analyses, along with a subgroup analysis based on disease stage. Of 252 patients included in this study, 206 had stage 2 ARONJ and 46 had stage 3 ARONJ. There were 119 patients with osteoporosis and 133 with malignant disease. In total, 139 patients were healed, and the healing rate of patients with stage 3 ARONJ was lower than that of patients with stage 2 ARONJ. With regard to the combination of surgery and HBO therapy, most patients underwent HBO before and after surgery. In the univariable analysis, surgery showed a therapeutic effect in both stage 2 and 3 ARONJ, whereas HBO showed a therapeutic effect in stage 2 ARONJ. In the multivariable analysis for stage 2 ARONJ, extensive surgery showed a stronger association with healing than conservative surgery, whereas \u226546 sessions of HBO therapy was less associated with healing than was non-HBO therapy. Our findings suggest that extensive surgery is highly effective against ARONJ regardless of disease stage if there is a sequestrum separation and systemic tolerance, whereas HBO therapy before and after surgical approach can be effective. Further studies are needed to identify treatment strategies for patients with treatment-refractory ARONJ who may be forced to undergo long-term HBO therapy with the expectation of sequestrum separation.<\/jats:p>","DOI":"10.1371\/journal.pone.0244859","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T18:56:15Z","timestamp":1609786575000},"page":"e0244859","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-1505","authenticated-orcid":true,"given":"Takuma","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-9869","authenticated-orcid":true,"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"pone.0244859.ref001","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"RE Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref002","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"K Fizazi","year":"2011","journal-title":"Lancet"},{"key":"pone.0244859.ref003","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","article-title":"Medication-related osteonecrosis of the jaw: a literature review","volume":"61","author":"S Kuroshima","year":"2019","journal-title":"J Oral Biosci"},{"key":"pone.0244859.ref004","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.joms.2019.03.040","article-title":"Surgical management of medication-related osteonecrosis of the jaw is associated with improved disease resolution: a retrospective cohort study","volume":"77","author":"M El-Rabbany","year":"2019","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","article-title":"Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study","volume":"47","author":"P Vescovi","year":"2011","journal-title":"Oral Oncol"},{"key":"pone.0244859.ref006","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.joms.2012.05.019","article-title":"Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases","volume":"70","author":"F Graziani","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref007","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.joms.2015.09.024","article-title":"Disease stage and mode of therapy are important determinants of treatment outcome for medication-related osteonecrosis of the jaw","volume":"73","author":"SL Ruggiero","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref008","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.joms.2016.12.014","article-title":"Extensive surgical procedures result in better treatment outcome for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis","volume":"75","author":"HY Kim","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref009","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/jbmr.3191","article-title":"Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis","volume":"32","author":"S Hayashida","year":"2017","journal-title":"J Bone Miner Res"},{"key":"pone.0244859.ref010","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.joms.2007.03.019","article-title":"Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series","volume":"65","author":"JJ Freiberger","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref011","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","article-title":"What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics","volume":"70","author":"JJ Freiberger","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref012","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update","volume":"72","author":"SL Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"T Yoneda","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"pone.0244859.ref014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","article-title":"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"O Nicolatou-Galitis","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"pone.0244859.ref015","first-page":"435","article-title":"Medication-related osteonecrosis of the jaw (MRONJ) stage \u2162: conservative and conservative surgical approaches versus an aggressive surgical intervention: a systematic review","volume":"48","author":"V Jasper","journal-title":"J Craniomaxillofac Surg. 2020"},{"key":"pone.0244859.ref016","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"T S\u00f6zen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"pone.0244859.ref017","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"ESMO Guidelines Working Group","year":"2014","journal-title":"Ann Oncol"},{"key":"pone.0244859.ref018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"AA Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"pone.0244859.ref019","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","volume":"35","author":"AA Khan","year":"2008","journal-title":"J Rheumatol"},{"key":"pone.0244859.ref020","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"JW Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"pone.0244859.ref021","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jcms.2017.05.027","article-title":"The impact of surgical intervention and antibiotics on MRONJ stage \u2161 and \u2162 - Retrospective study","volume":"45","author":"M Zirk","year":"2017","journal-title":"J Craniomaxillofac Surg"},{"key":"pone.0244859.ref022","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/cre2.303","article-title":"Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study","volume":"6","author":"M Albanese","year":"2020","journal-title":"Clin Exp Dent Res"},{"key":"pone.0244859.ref023","article-title":"Retrospective analysis of bacterial colonization of necrotic bone and antibiotic resistance in 98 patients with medication-related osteonecrosis of the jaw (MRONJ)","author":"F Ewald","year":"2020","journal-title":"Clin Oral Investig"},{"key":"pone.0244859.ref024","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10006-018-0732-8","article-title":"A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw","volume":"22","author":"M Akashi","year":"2018","journal-title":"Oral Maxillofac Surg"},{"key":"pone.0244859.ref025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.oraloncology.2014.08.016","article-title":"A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)","volume":"50","author":"K Rupel","year":"2014","journal-title":"Oral Oncol"},{"key":"pone.0244859.ref026","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/01.ASW.0000280198.81130.d5","article-title":"Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study","volume":"20","author":"JV Boykin","year":"2007","journal-title":"Adv Skin Wound Care"},{"key":"pone.0244859.ref027","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1152\/japplphysiol.91109.2008","article-title":"Two faces of nitric oxide: implications for cellular mechanisms of oxygen toxicity","volume":"106","author":"BW Allen","year":"2009","journal-title":"J Appl Physiol"},{"key":"pone.0244859.ref028","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/app9051026","article-title":"A systematic review of oxygen therapy for the management of medication-related osteonecrosis of the jaw (MRONJ)","volume":"9","author":"R Sacco","year":"2019","journal-title":"Appl Sci"},{"key":"pone.0244859.ref029","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0278-2391(83)80005-6","article-title":"A new concept in the treatment of osteoradionecrosis","volume":"41","author":"RE Marx","year":"1983","journal-title":"J Oral Maxillofac Surg"},{"key":"pone.0244859.ref030","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.ijom.2016.06.016","article-title":"Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences","volume":"45","author":"K Grisar","year":"2016","journal-title":"Int Oral Maxillofac Surg"},{"key":"pone.0244859.ref031","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1532\/IJH97.06110","article-title":"Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma","volume":"84","author":"K Shimura","year":"2006","journal-title":"Int J Hematol"},{"key":"pone.0244859.ref032","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10266-013-0129-y","article-title":"FDG-PET may predict the effectiveness of hyperbaric oxygen therapy in a patient with bisphosphonate-related osteonecrosis of the jaw: report of a case","volume":"103","author":"CN Fatema","year":"2015","journal-title":"Odontology"},{"key":"pone.0244859.ref033","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1563\/1548-1336(2007)33[371:UOPPIT]2.0.CO;2","article-title":"Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases","volume":"33","author":"CYS Lee","year":"2007","journal-title":"J Oral Implantol"},{"key":"pone.0244859.ref034","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/ID.0b013e3182310f03","article-title":"Identification and treatment of bisphosphonate-associated actinomycotic osteonecrosis of the jaws","volume":"20","author":"CYS Lee","year":"2011","journal-title":"Implant Dent"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T18:56:26Z","timestamp":1609786586000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244859"}},"subtitle":[],"editor":[{"given":"Essam","family":"Al-Moraissi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244859","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]}}}